Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Releases Earnings Results, Misses Estimates By $0.23 EPS

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) released its quarterly earnings data on Tuesday. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23), FiscalAI reports.

Damora Therapeutics, Inc. Common Stock Trading Down 5.2%

DMRA stock traded down $1.27 during midday trading on Tuesday, reaching $23.09. 520,843 shares of the company’s stock traded hands, compared to its average volume of 254,854. Damora Therapeutics, Inc. Common Stock has a 52-week low of $2.45 and a 52-week high of $38.33. The stock has a market cap of $1.39 billion, a P/E ratio of -1.91 and a beta of 1.50. The stock’s 50-day moving average is $26.02 and its 200 day moving average is $23.72.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Hedge funds and other institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $40,000. Geode Capital Management LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter worth $266,000. Virtu Financial LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the third quarter worth $49,000. Two Sigma Investments LP bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the third quarter worth $76,000. Finally, Connective Capital Management LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the third quarter worth $100,000. 14.20% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on DMRA. Evercore began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They set an “outperform” rating and a $46.00 target price on the stock. UBS Group initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. They set a “buy” rating and a $45.00 target price on the stock. Lifesci Capital raised shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, February 2nd. Royal Bank Of Canada initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They set an “outperform” rating and a $40.00 price objective on the stock. Finally, Guggenheim reissued a “buy” rating and set a $40.00 price objective (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $43.40.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical?stage biotechnology company developing small?molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin?3, an extracellular carbohydrate?binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase?like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin?3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin?3 inhibitor being evaluated for systemic fibrotic disorders.